Kurser indlæses...
Prognose
Analytikernes gennemsnitlige kursmål er 13,68 € (+129,92 %). Medianen er 13,68 € (+129,92 %).
| Køb |
5 |
| Behold |
0 |
| Sælg |
0 |
Diskussioner i communityet
Der er endnu ingen diskussion om dette aktiv.
Start diskussionNyheder Til nyhedsfeedet
ImmunityBio stock rises after ANKTIVA approval in the UAE
ImmunityBio shares climbed 7.5% after ANKTIVA was approved in the United Arab Emirates. The approval covers ANKTIVA 0.4 mg in combination with BCG for the treatment of adult patients with BCG-unresponsive, non‑muscle‑invasive bladder cancer and ANKTIVA 1.2 mg with immune checkpoint inhibitors for metastatic non‑small‑cell lung cancer. The approval expands ANKTIVA’s regulatory presence to 34 countries and is based on the QUILT‑3.032 study (in NMIBC: 71% complete response rate in the CIS cohort; 12‑month DFR 58.2% in papillary tumors; 83% cystectomy‑free at 36 months) and QUILT‑3.055 (in checkpoint‑refractory NSCLC: median overall survival 14.6 months). » Mere på de.investing.com
ImmunityBio analysis: ANKTIVA plus BCG significantly more cost-effective than TAR-200 in bladder cancer
A health economic analysis presented in Philadelphia shows that ANKTIVA combined with BCG achieves substantial cost savings over three years compared with TAR-200 for BCG-unresponsive, non–muscle-invasive bladder cancer. Savings per avoided cystectomy were $109,622 in year 1, $151,438 in year 2 and $60,393 in year 3; savings per cystectomy-free month were $9,370, $6,144 and $1,520 in years 1–3, respectively. The study attributed the cost reductions to lower acquisition and administration costs and slightly higher complete response rates (49.6% vs. 45.9%). Investors reacted positively; the stock has returned 272% in the past six months and is trading at $7.74. » Mere på de.investing.com
ImmunityBio obtains exclusive US rights to Tokio-172 BCG
ImmunityBio has signed an exclusive development and supply agreement with Japan BCG Laboratory for the Tokio-172 BCG strain in the U.S. and could become the sole BLA applicant. The decision is based on Phase III SWOG S1602 data showing non-inferiority to TICE BCG (HR 0.82) and an estimated 5-year recurrence-free survival of 64% vs. 58%. Tokio-172 is not yet FDA-approved in the U.S.; ImmunityBio is in discussions with the FDA and research institutions about data use and plans regulatory steps. The company reports strong revenue growth but remains unprofitable, and analysts see further upside potential despite recent share gains. » Mere på de.investing.com
ImmunityBio posts strong Anktiva sales growth and expands global access
ImmunityBio reported accelerating commercial traction for Anktiva with Q4 2025 net product revenue up 700% year‑over‑year and unit volumes rising 750%, driven by broadened physician and patient adoption. The company has expanded Anktiva access to 33 countries across four major regulatory jurisdictions and secured an FDA J‑code to improve reimbursement visibility. ImmunityBio is advancing a multi‑layered immunotherapy platform—Anktiva (IL‑15 superagonist), NaNT allogeneic cell therapy, DNA vaccines and Leonardo manufacturing for off‑the‑shelf NK/CAR‑NK products—that management says could scale into an API‑like personalized immune regimen and materially re‑rate the company if execution continues. Continued commercial momentum and regulatory tailwinds underpin a bullish long‑term thesis for IBRX, albeit with execution risk. » Mere på finance.yahoo.com
ImmunityBio posts 168% y/y product revenue jump as ANKTIVA launch gains traction
ImmunityBio reported preliminary results for the quarter ending March 31, 2026, with product revenue rising 168% year over year to $44.2 million following the commercial launch of ANKTIVA. The company recorded $113 million net product revenue in 2025 (up 700% from 2024) and ended the quarter with $380.9 million in cash and cash equivalents. ANKTIVA has regulatory approval across five jurisdictions covering 34 countries, and ImmunityBio is focused on scaling U.S. commercialization and global expansion to broaden revenue streams. » Mere på finance.yahoo.com
Historisk udbytte Udbytte
Alle nøgletal for udbytte Alle nøgletalVirksomhedstal
| (EUR) | september 2026 | YoY |
|---|---|---|
| Omsætning | 43,12 mio. | 57,83 % |
| Bruttofortjeneste | 41,98 mio. | 76,37 % |
| Nettoresultat | -162,93 mio. | 184,30 % |
| EBITDA | -131,24 mio. | 330,53 % |
Fundamentale data
| Nøgletal | Værdi |
|---|---|
Markedsværdi | 6,07 mia. € |
Antal aktier | 1,06 mia. |
Højeste/laveste i 52 uger | 11,33 € - 1,78 € |
Udbytteafkast | 1,05 % |
Udbytte TTM | 0,0574 € |
Beta | 0,13 |
P/E (PE Ratio) | -5,84 |
PEG (PEG Ratio) | 0,05 |
K/I (PB Ratio) | -5,79 |
P/S (PS Ratio) | 36,48 |
Virksomhedsprofil
ImmunityBio, Inc., et klinisk-stadie bioteknologiselskab, udvikler terapier og vacciner til behandling af kræft og infektionssygdomme. Selskabet tilbyder immunterapi- og celleterapiplatforme, herunder antistof-cytokin-fusionsproteiner, syntetiske immunmodulatorer, vaccineteknologier, naturlige dræberceller (NK-celler) og adaptive (T-celle) immunsystemer. Selskabet udvikler desuden terapeutiske midler, som er i fase II- eller III-kliniske forsøg til behandling af flydende og solide tumorer, herunder blære-, bugspytkirtel- og lungekræft, samt patogener som SARS-CoV-2 og HIV. Selskabet har samarbejdsaftaler med National Cancer Institute, National Institute of Deafness and Communication Disorders og Amyris, Inc.; og licensaftaler med CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc. og Viracta Therapeutics, Inc. Selskabet blev grundlagt i 2014 og har hovedsæde i San Diego, Californien.
| Navn | ImmunityBio |
| CEO | Richard Gerald Adcock |
| Hjemsted | San Diego,
ca USA |
| Websted | |
| Sektor | Sundhed |
| Branche | Bioteknologi |
| Børsnotering | 28.07.2015 |
| Medarbejdere | 688 |
Tickersymboler
| Børs | Symbol |
|---|---|
NASDAQ | IBRX |
Frankfurt | 26CA.F |
Düsseldorf | 26CA.DU |
München | 26CA.MU |